Pipeline Overview

Therapeutic Development Progress

Airway Therapeutics is advancing zelpultide alfa across multiple indications. The therapy is currently in Phase 2b/3 trials for very preterm neonates with bronchopulmonary dysplasia (BPD).

Beyond BPD, the company is actively exploring zelpultide alfa’s potential in a broad spectrum of respiratory, inflammatory, and infectious conditions, including chronic obstructive pulmonary disease (COPD), pneumonia, acute respiratory distress syndrome (ARDS), lung fibrosis, and Influenza A.

AIRWAY Pipeline
Indication
Discovery
PreIND
IND Approval
Phase 1
Phase 2
Phase 3
BPD
Pneumonia / ARDS
COPD
Flu
Pulmonary Fibrosis
Additional Indications: • Asthma • RSV • Osteoarthitis
*BPD= bronchopulmonary dysplasia; ARDS= acute respiratory distress syndrome; COPD= chronic obstructive pulmonary disease; RSV= respiratory syncytial virus